Suppr超能文献

用于高效通读活性的构象受限负霉素衍生物的开发。

Development of Conformationally Restricted Negamycin Derivatives for Potent Readthrough Activity.

作者信息

Omura Noriko, Taguchi Akihiro, Kuwahara Tomoki, Hamada Keisuke, Watanabe Mizuki, Nakakuki Masanori, Konno Sho, Takayama Kentaro, Taniguchi Atsuhiko, Nomura Toshifumi, Shuto Satoshi, Hayashi Yoshio

机构信息

Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, Hokkaido 060-0812, Japan.

出版信息

ACS Med Chem Lett. 2023 Dec 4;14(12):1807-1814. doi: 10.1021/acsmedchemlett.3c00424. eCollection 2023 Dec 14.

Abstract

(+)-Negamycin, which is a dipeptide-like antibiotic containing a hydrazide structure, exhibits readthrough activity, resulting in the restoration of dystrophin in the mouse model of Duchenne muscular dystrophy (DMD). In our previous structure-activity relationship study of negamycin, we found that its natural analogue 3--deoxynegamycin (TCP-107), without antimicrobial activity, showed a higher readthrough activity than negamycin. In this study, we designed and synthesized cyclopropane-based conformationally restricted derivatives of TCP-107 and evaluated their readthrough activity in the cell-based reporter assay against a TGA-type mutation derived from DMD. As a result, a down- isomer, TCP-304, showed significant readthrough activity among the four isomers. Moreover, TCP-306, a derivative acylated by l-α-aminoundecanoic acid, possessed approximately 3 times higher activity than TCP-304. These down- derivatives showed dose-dependent readthrough activity and were effective for not only TGA but also TAG mutations. These results suggest that the conformational restriction of negamycin derivatives by the introduction of the cyclopropane ring is effective for an exhibition of potent readthrough activity.

摘要

(+)-Negamycin是一种含有酰肼结构的二肽类抗生素,具有通读活性,可使杜氏肌营养不良症(DMD)小鼠模型中的抗肌萎缩蛋白得以恢复。在我们之前对negamycin的构效关系研究中,我们发现其天然类似物3 - 脱氧negamycin(TCP-107)虽无抗菌活性,但通读活性却高于negamycin。在本研究中,我们设计并合成了基于环丙烷的TCP-107构象受限衍生物,并在基于细胞的报告基因检测中评估了它们针对源自DMD的TGA型突变的通读活性。结果,在四种异构体中,反式异构体TCP-304表现出显著的通读活性。此外,由L-α-氨基十一烷酸酰化的衍生物TCP-306,其活性比TCP-304高约3倍。这些反式衍生物表现出剂量依赖性通读活性,不仅对TGA有效,对TAG突变也有效。这些结果表明,通过引入环丙烷环对negamycin衍生物进行构象限制,对于展现强效通读活性是有效的。

相似文献

1
Development of Conformationally Restricted Negamycin Derivatives for Potent Readthrough Activity.
ACS Med Chem Lett. 2023 Dec 4;14(12):1807-1814. doi: 10.1021/acsmedchemlett.3c00424. eCollection 2023 Dec 14.
2
Structure-Activity Relationship Studies of 3-epi-Deoxynegamycin Derivatives as Potent Readthrough Drug Candidates.
ACS Med Chem Lett. 2015 May 11;6(6):689-94. doi: 10.1021/acsmedchemlett.5b00121. eCollection 2015 Jun 11.
3
New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.
ACS Med Chem Lett. 2019 Sep 23;10(10):1450-1456. doi: 10.1021/acsmedchemlett.9b00273. eCollection 2019 Oct 10.
4
Structure-Activity Relationship Study of Leucyl-3--deoxynegamycin for Potent Premature Termination Codon Readthrough.
ACS Med Chem Lett. 2017 Sep 29;8(10):1060-1065. doi: 10.1021/acsmedchemlett.7b00269. eCollection 2017 Oct 12.
5
Negamycin analogue with readthrough-promoting activity as a potential drug candidate for duchenne muscular dystrophy.
ACS Med Chem Lett. 2012 Jan 2;3(2):118-22. doi: 10.1021/ml200245t. eCollection 2012 Feb 9.
6
Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.
J Antibiot (Tokyo). 2018 Feb;71(2):205-214. doi: 10.1038/ja.2017.112. Epub 2017 Sep 27.
8
Influence of novel readthrough agents on myelin protein zero translation in the peripheral nervous system.
Neuropharmacology. 2022 Jun 15;211:109059. doi: 10.1016/j.neuropharm.2022.109059. Epub 2022 Apr 10.
9
Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice.
J Biochem. 2003 Nov;134(5):751-8. doi: 10.1093/jb/mvg203.
10
Ubr1p-Cup9p-Ptr2p pathway involves in the sensitivity to readthrough compounds negamycin derivatives in budding yeast.
Biosci Biotechnol Biochem. 2019 Oct;83(10):1889-1892. doi: 10.1080/09168451.2019.1625263. Epub 2019 Jun 4.

引用本文的文献

1
Direct nitrogen-nitrogen bond formation by an enzyme from the negamycin biosynthetic pathway.
Nat Chem Biol. 2025 Jul;21(7):987-988. doi: 10.1038/s41589-025-01899-z.
2
A heme-dependent enzyme forms the hydrazine in the antibiotic negamycin.
Nat Chem Biol. 2025 May 1. doi: 10.1038/s41589-025-01898-0.

本文引用的文献

1
Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets.
ACS Med Chem Lett. 2021 Aug 9;12(9):1486-1492. doi: 10.1021/acsmedchemlett.1c00349. eCollection 2021 Sep 9.
2
Structural Revision of Natural Cyclic Depsipeptide MA026 Established by Total Synthesis and Biosynthetic Gene Cluster Analysis.
Angew Chem Int Ed Engl. 2021 Apr 12;60(16):8792-8797. doi: 10.1002/anie.202015193. Epub 2021 Mar 8.
3
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease.
Expert Opin Investig Drugs. 2020 Dec;29(12):1347-1354. doi: 10.1080/13543784.2020.1828862. Epub 2020 Oct 12.
4
2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations.
Nat Commun. 2020 Mar 20;11(1):1509. doi: 10.1038/s41467-020-15140-z.
5
New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.
ACS Med Chem Lett. 2019 Sep 23;10(10):1450-1456. doi: 10.1021/acsmedchemlett.9b00273. eCollection 2019 Oct 10.
6
Aminoglycoside interactions and impacts on the eukaryotic ribosome.
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10899-E10908. doi: 10.1073/pnas.1715501114. Epub 2017 Dec 5.
7
From Peptides to Peptidomimetics: A Strategy Based on the Structural Features of Cyclopropane.
Chemistry. 2017 Oct 17;23(58):14394-14409. doi: 10.1002/chem.201702119. Epub 2017 Aug 22.
9
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
J Med Chem. 2016 Oct 13;59(19):8712-8756. doi: 10.1021/acs.jmedchem.6b00472. Epub 2016 Jun 30.
10
Corticosteroids for the treatment of Duchenne muscular dystrophy.
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验